

UCLA

UCLA Previously Published Works

Title

Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder

Permalink

<https://escholarship.org/uc/item/6p6194hc>

Journal

American Journal of Psychiatry, 172(12)

ISSN

0002-953X

Authors

Scahill, Lawrence
McCracken, James T
King, Bryan H
et al.

Publication Date

2015-12-01

DOI

10.1176/appi.ajp.2015.15010055

Peer reviewed

Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder

Lawrence Scahill, M.S.N., Ph.D., James T. McCracken, M.D., Bryan H. King, M.D., Carol Rockhill, M.D., Bhavik Shah, M.D., Laura Politte, M.D., Roy Sanders, M.D., Mendy Minjarez, Ph.D., Jennifer Cowen, Ph.D., Jennifer Mullett, R.N., Chris Page, B.S., Denise Ward, M.A., Yanhong Deng, M.P.H., Sandra Loo, Ph.D., James Dziura, Ph.D., Christopher J. McDougle, M.D., Research Units on Pediatric Psychopharmacology Autism Network

Objective: Hyperactivity, impulsiveness, and distractibility are common problems in children with autism spectrum disorder (ASD). Extended-release guanfacine is approved for children with attention deficit hyperactivity disorder but not well studied in ASD.

Method: In a multisite, randomized clinical trial, extended-release guanfacine was compared with placebo in children with ASD accompanied by hyperactivity, impulsiveness, and distractibility.

Results: Sixty-two subjects (boys, N=53; girls, N=9; mean age=8.5 years [SD=2.25]) were randomly assigned to guanfacine (N=30) or placebo (N=32) for 8 weeks. The guanfacine group showed a 43.6% decline in scores on the Aberrant Behavior Checklist-hyperactivity subscale (least squares mean from 34.2 to 19.3) compared with a 13.2% decrease in the placebo group (least squares mean from 34.2 to 29.7; effect size=1.67). The rate of positive response (much improved or very much improved on the Clinical Global Impression-Improvement scale) was 50%

(15 of 30) for guanfacine compared with 9.4% (3 of 32) for placebo. A brief cognitive battery tapping working memory and motor planning showed no group differences before or after 8 weeks of treatment. The modal dose of guanfacine at week 8 was 3 mg/day (range: 1–4 mg/day), and the modal dose was 3 mg/day (range: 2–4 mg/day) for placebo. Four guanfacine-treated subjects (13.3%) and four placebo subjects (12.5%) exited the study before week 8. The most common adverse events included drowsiness, fatigue, and decreased appetite. There were no significant changes on ECG in either group. For subjects in the guanfacine group, blood pressure declined in the first 4 weeks, with return nearly to baseline by endpoint (week 8). Pulse rate showed a similar pattern but remained lower than baseline at endpoint.

Conclusions: Extended-release guanfacine appears to be safe and effective for reducing hyperactivity, impulsiveness, and distractibility in children with ASD.

AJP in Advance (doi: 10.1176/appi.ajp.2015.15010055)

The pervasive developmental disorders (autistic disorder, pervasive developmental disorder not otherwise specified, and Asperger's syndrome) defined in DSM-IV (1) have been subsumed under the single diagnostic category of autism spectrum disorder (ASD) in DSM-5 (2). A recent detailed review of epidemiological studies estimates an ASD prevalence of 6.2 per 1,000 children worldwide (3). Of these, 30%–40% are intellectually disabled (3).

In addition to essential diagnostic characteristics, children with ASD may exhibit serious behavioral problems such as tantrums, aggression and self-injury (4), and anxiety (5), as well as hyperactivity, impulsiveness, and distractibility (6–8). Although DSM-IV advised against giving a diagnosis of attention deficit hyperactivity disorder (ADHD) to children with ASD (1), DSM-5 discarded this convention (2). When present, hyperactivity, impulsiveness, and distractibility add

to the overall impairment in children with ASD (9). Not surprisingly, stimulants and alpha₂ agonists are commonly used to treat ADHD symptoms in children with ASD (10).

Few studies have rigorously tested treatments of ADHD symptoms in children with ASD. The alpha₂ agonists clonidine and guanfacine have been evaluated in open and small randomized trials among children with ASD, with inconclusive results on efficacy and recurring problems with sedation and irritability (11). Using a double-blind crossover design, our research group previously tested three dose levels of immediate-release methylphenidate in 72 children with ASD (12). All three dose levels of methylphenidate were superior to placebo, with score reductions of small to medium effect sizes on the Aberrant Behavior Checklist-hyperactivity subscale. The overall positive response rate on the Clinical Global Impression-Improvement (CGI-I) scale of 49% was

lower than the 65%–70% positive response rate in children with ADHD uncomplicated by ASD (13, 14). Furthermore, adverse effects occurred at higher than expected rates in children with ASD compared with children with ADHD uncomplicated by ASD (12, 14). Harfterkamp et al. (15) reported equivocal results in an 8-week placebo-controlled trial of atomoxetine in 97 children with ASD and ADHD symptoms. Collectively, these results suggest that additional pharmacological strategies are needed for children with ASD and ADHD symptoms for whom stimulants are not effective or intolerable. We previously conducted an open-label trial of immediate-release guanfacine in 25 subjects with a recent history of failed treatment with methylphenidate. In that study, we observed a 39% reduction on the Aberrant Behavior Checklist hyperactivity subscale and a 48% (12 of 25) positive response rate on the improvement item of the CGI (16, 17). The purpose of the present study was to test whether extended-release guanfacine would be superior to placebo in children with an ASD accompanied by moderate to severe hyperactivity.

METHOD

Design

This was a five-site randomized, double-blind placebo-controlled, fixed-flexible dose clinical trial conducted by the Research Units on Pediatric Psychopharmacology Autism Network. Using permuted blocks to conceal allocation, eligible subjects were randomly assigned within site without stratification in a 1:1 ratio to extended-release guanfacine or placebo for 8 weeks. At week 8, subjects who met predetermined criteria for positive response (see below) in the double-blind phase continued with their randomized treatment (extended-release guanfacine or placebo) for 8 more weeks without breaking the treatment mask. The treatment blind was broken for subjects who did not show a positive response. Subjects who were randomly assigned to placebo and did not show a positive response were offered open-label treatment with extended-release guanfacine for 8 weeks. Subjects who showed insufficient response to guanfacine in the double-blind phase were tapered off the medication and managed outside of the study. This report focuses on the results of the acute double-blind phase.

Setting and Subjects

The study was approved by the institutional review board at each site (University of California at Los Angeles, Emory University, Massachusetts General Hospital, University of Washington at Seattle, and Yale University) and registered with Clinicaltrials.gov (NCT01238575). Study subjects were recruited from clinic registries, current referrals to the active clinical programs at each site, local website announcements, and outreach to parent support groups. No study data were collected until a parent (or guardian) signed the informed consent. Protocol adherence was monitored through weekly teleconferences with the principal investigators and

coordinators. The coordinating centers (Yale University and Emory University) conducted semiannual site visits and managed study data. An external data, safety, and monitoring board reviewed safety, enrollment, and attrition three times a year.

An experienced multidisciplinary team at each site conducted the screening, baseline, and follow-up assessments. To be eligible, subjects had to be between 5 and 14 years of age with a DSM-IV diagnosis of autistic disorder, Asperger's syndrome, or pervasive developmental disorder not otherwise specified, based on clinical assessment and corroborated by the Autism Diagnostic Observation Schedule (18) and the Social Communication Questionnaire (19). The Autism Diagnostic Observation Schedule is a clinician-administered procedure that places the child in naturalistic social situations designed to elicit social and communication responses. The Social Communication Questionnaire is a 40-item parent-completed survey that evaluates the child's communication and social functioning. The lifetime version of the questionnaire provides a total score that can be compared against normative data as further support for an ASD diagnosis. The pretreatment assessment also included routine laboratory tests (blood counts, electrolytes, liver function tests, blood urea nitrogen, creatinine, and urinalysis), medical and psychiatric histories, a physical examination, and vital sign evaluation. The screening and week-8 ECG were reviewed by a pediatric cardiologist at each site.

The primary targets of the treatment were hyperactivity, impulsiveness, and distractibility. Therefore, we set a minimum score of 24 on the parent-rated Aberrant Behavior Checklist-hyperactivity subscale for study eligibility (see below). In addition, a Clinical Global Impression-Severity (CGI-S) score of moderate or greater was required for entry. The CGI is a 7-item scale, which ranges from 1 (normal) through 4 (moderate) to 7 (extreme), designed to rate overall symptom severity (17). In addition to hyperactivity, impulsiveness, and distractibility, raters considered all aspects of the child's clinical picture to assign the CGI-S score.

Based on the Abbreviated Stanford-Binet Intelligence Scales (20) or the Mullen Scales of Early Learning (21), subjects had to have an IQ of 35 (or mental age of 18 months) or greater. Anticonvulsant medication for seizures was allowed if the dose was stable (at least 4 weeks) and the subject was seizure-free for at least 6 months. Otherwise, subjects had to be medication-free prior to baseline. Subjects taking a psychotropic treatment deemed ineffective were required to be withdrawn from the medication for at least 1 week for stimulants or clonidine, 2 weeks for atomoxetine and most antidepressants, and 3 weeks for fluoxetine, citalopram, and antipsychotics. Children with a significant medical condition by history, physical examination, or laboratory testing were excluded. Girls with a positive pregnancy test were also excluded.

To screen for other DSM-IV disorders, we relied on clinical evaluation supplemented by the parent-completed Child and Adolescent Symptom Inventory (22). This 132-item

DSM-IV-based checklist asks parents to rate symptoms in the major psychiatric disorders of childhood on a 4-point scale (0=never; 1=sometimes; 2=often; and 3=very often). Scores of 2 or 3 are regarded as a positive symptom for the given disorder. Children with a lifetime diagnosis of psychosis or bipolar disorder or current diagnosis of major depression, obsessive-compulsive disorder, or substance abuse were excluded. To assess adaptive functioning at baseline, we used the parent-rated Vineland Adaptive Behavior Scales II (Vineland II) (23). The Vineland II provides standard scores in three domains: communication, socialization, and daily living skills. Prior to administration, parents were instructed to consider adaptive skills that the child is unable to perform (score of 0); skills that the child performs sometimes (score of 1); and skills that the child regularly performs (score of 2).

Outcome Measures

The primary outcome measure was the parent-rated Aberrant Behavior Checklist-hyperactivity subscale (9, 24, 25). The full Aberrant Behavior Checklist is a 58-item parent rating with five factors: irritability, social withdrawal, stereotypy, hyperactivity, and inappropriate speech. The 16-item hyperactivity subscale (collected at baseline, weeks 4, 6, and 8) covers over-activity (seven items), impulsiveness (two items), inattention (three items), and noncompliance (four items). It has been used as a primary outcome measure in several trials of children with developmental disabilities (12, 16).

Two blinded clinicians followed each subject: a treating clinician and an independent evaluator. The treating clinician adjusted the dose of the medication and monitored adverse events. The independent evaluator assessed key secondary outcomes, including scores for the improvement item of the CGI (17) and the ADHD Rating Scale (26). To protect the blind, the independent evaluator did not discuss adverse effects or dosing. The ADHD Rating Scale is an 18-item scale directly derived from DSM-IV criteria for ADHD with established reliability, validity, and sensitivity to change (26–28). The CGI-I is a 7-point scale designed to measure overall symptomatic change compared with baseline. Scores range from 1 (very much improved) through 4 (unchanged) to 7 (very much worse). A rating of much improved or very much improved on the CGI-I at week 8 was used to define positive response. As noted, the treatment mask was broken for subjects who did not show a positive response. The blind was broken by the treating clinician, and treatment status was not disclosed to independent evaluators.

Experienced investigators (L.S., B.K.) trained study independent evaluators on the CGI (severity and improvement) using case vignettes for illustration and discussion. To be considered reliable, raters had to be in full agreement on the CGI (severity and improvement) with the gold standard score on at least one vignette. In addition, independent evaluators had to be within one unit of the gold standard without disagreement on study eligibility or treatment response on two other vignettes. For example, if the gold standard baseline CGI-S was moderate (4) and the new rater gave a score of mild

(3), this one unit difference would affect eligibility and was considered unreliable. Similarly, on the CGI-I, if the gold standard score was 2 (much improved) and the new rater gave a score of 3 (minimally improved), this was unacceptable because of the disagreement on classification. Independent evaluators also received training on the administration of the ADHD Rating Scale and had to be within 4 points on two video recordings compared with the expert rater. Independent evaluators participated in monthly conference calls to review cases and to promote a common approach to conducting assessments across sites.

Four cognitive tests were administered at baseline and week 8 by psychologists who were trained to reliability and blind to treatment assignment. The tests included the Recognition of Pictures and Digit Recall subtests from the Differential Ability Scales II (29) and the Imitating Hand Positions and Manual Motor Sequences from the sensorimotor domain of the NEPSY II (30). To assess working memory, the Recognition of Pictures presents pictures of objects for 5–10 seconds to the child. The examiner then presents a new page with the same objects mixed with distracter pictures and asks the child to point to the original objects. The Recall of Digits is also a working memory task in which the child is asked to repeat a sequence of digits presented orally by the examiner. Sequences start with two digits and increase progressively up to nine digits or until the child meets the discontinuation rule. The Imitating Hand Positions test assesses motor planning by asking the child to imitate the examiner's hand and finger positions with the dominant hand, nondominant hand, and both hands. The Manual Motor Sequences task measures the ability of the child to imitate a series of rhythmic movements by the examiner using one or both hands.

Medication Schedule

The extended-release guanfacine formulation is undermined if the tablets are crushed or broken. Thus, we confirmed that each subject was able to swallow the whole tablet. The starting morning dose for all children was 1 mg per day. Children weighing less than 25 kg remained on the 1-mg dose until day 14. If the medication was well-tolerated, the dose could be raised to 2 mg until day 28 and increased to 3 mg for the remaining 4 weeks in the trial. Children weighing 25 kg or more were eligible for an increase to 2 mg at day 7, 3 mg at day 14, and 4 mg at day 21 or day 28. The dose schedule was not fixed; the treating clinician could delay a planned increase or lower the dose to manage adverse effects. The treating clinician could also switch to an evening dose to manage daytime drowsiness.

Safety Monitoring

Subjects were seen weekly for the first 4 weeks, then at weeks 6 and 8. Blood pressure and pulse sitting at rest and height and weight were measured at each visit. Routine laboratory tests were not repeated at week 8 in the absence of evidence that guanfacine affects these indices (31, 32). An

ECG was obtained at week 8 (or early termination) to assess the impact of guanfacine on cardiac conduction.


Adverse events were also systematically reviewed and documented at each visit. At baseline, the treating clinician conducted the 34-item Pretreatment Health and Behavior Review, developed by the Research Units on Pediatric Psychopharmacology Autism Network (4, 12), to collect pre-treatment data on mild, moderate, or severe health complaints, as well as activity level, appetite, bowel function, sleep, and dermatological problems. Following a similar format, the treating clinician reviewed the 34-item Adverse Event Review to identify new adverse effects after random assignment. New adverse events, whether presumed related to treatment or not, were rated as mild (no impairment), moderate (some impairment or need for intervention to prevent impairment), severe (evidence of impairment and need for intervention), serious (need for hospitalization or major threat to health and well-being). A decrease of 10 mm of Hg in diastolic blood pressure or a shift into the abnormal range (i.e., >2 standard deviations below the normal range for age and gender) was documented as an adverse event. For these subjects, blood pressure was repeated after a 5- to 10-minute resting period. If the 10-mm drop in the diastolic blood pressure persisted on repeat measurement during the same visit, the dose was reduced.

Analytic Plan

The population mean score on the Aberrant Behavior Checklist-hyperactivity subscale for developmentally disabled boys in this age group was 13 (SD=11.3) (slightly lower for girls). Study eligibility required a medication-free Aberrant Behavior Checklist-hyperactivity subscale score >24. To estimate sample size, we predicted a mean hyperactivity subscale score at baseline of 30 (SD=10) (approximately 1.5 standard deviations above the population mean). Based on previous studies, we predicted incremental, linear improvement for extended-release guanfacine over time. We estimated the power to detect a clinically meaningful effect size of 0.55 across a range of sample sizes in a series of simulations using a random regression model. To estimate the correlation of repeated parent-rated Aberrant Behavior Checklist-hyperactivity subscale scores, we used data from subjects randomly assigned to placebo in our previous trial comparing risperidone with placebo (4). The correlations ranged from 0.63–0.85 over that 8-week trial. For the linear trend hypothesis, a sample size of 60 provided 85.5% power assuming a test-retest correlation of 0.7 on the Aberrant Behavior Checklist-hyperactivity subscale. Power would be slightly reduced if the correlation were 0.63 and greater if the correlation were 0.8.

All randomly assigned subjects were included in the intent-to-treat analyses. Preliminary analyses included descriptive statistics for baseline measures in each treatment group, as well as examination of scores within each group at weeks 4 and 8. To evaluate the effect of treatment over time, we used a mixed-effect linear model on the

FIGURE 1. CONSORT Diagram of Study Flow



* Two additional subjects discontinued treatment because of adverse events but remained in the study.

primary outcome measure (parent-rated Aberrant Behavior Checklist-hyperactivity subscale). Study group and site were the fixed effects; time and outcome were the random effects (33). Using the baseline Aberrant Behavior Checklist-hyperactivity subscale score as a fixed effect in the model, each subject's response was modeled by regressing the score against time. The intercept and slope of the regression were allowed to vary randomly between subjects. A linear contrast of group differences at 8 weeks (i.e., clinical response) was performed and tested for statistical significance. We used a similar approach for the key secondary outcome, the ADHD Rating Scale score collected at baseline, week 4, and week 8. To evaluate overall improvement, we compared the proportion of subjects rated as much improved or very much improved on the CGI-I by the independent evaluator in each treatment group using chi-square analysis.

All analyses were conducted using SAS/STAT software, version 9.3. In addition, p values ≤ 0.05 were accepted as statistically significant for the Aberrant Behavior Checklist-hyperactivity subscale, the ADHD Rating Scale, and the CGI-I, with Bonferroni correction for other Aberrant Behavior Checklist subscales. The analysis proceeded on the assumption that missing data were missing at random. Although there is no proven method for verifying this assumption, we compared selected demographic and clinical characteristics of subjects who dropped out with these characteristics in the remaining sample (34). The rate of adverse effects greater than 5% was compared across treatment groups by chi-square analysis; p values ≤ 0.10 were considered statistically significant for adverse events.

RESULTS

Eighty-one children were screened; 62 (boys, N=53; girls, N=9) eligible subjects were randomly assigned to extended-release guanfacine (N=30) or placebo (N=32) (Figure 1). Subjects ranged in age from 5 to 14 years (mean=8.5 years [SD=2.25]). There were no differences in demographic and clinical characteristics between treatment groups (see Table 1). Eight subjects (12.9%) dropped out before week 8 (four from each group). The demographic and baseline clinical characteristics for these eight subjects were not different than these characteristics for the 54 subjects who completed the trial. Thirty-four subjects (54.8%) were drug naive. Twenty-six children (41.9%) were medication-free at screening but had been treated with various medications in the past. In collaboration with the child's primary clinician, parents decided to discontinue a current medication for two subjects (3.2%). One subject entered following a 3-week washout of fluoxetine, and one entered following a 4-week washout of aripiprazole.

Table 2 shows that guanfacine was superior to placebo on the parent-rated Aberrant Behavior Checklist-hyperactivity subscale ($p<0.001$, effect size=1.67) and the clinician-rated ADHD Rating Scale ($p<0.001$ for all three measures). The change in the least-squares means on the Aberrant Behavior Checklist-hyperactivity subscale over the 8-week trial is presented in Figure 2. The guanfacine group showed a 43.6% decline in the Aberrant Behavior Checklist-hyperactivity subscale score (least-squares mean values were 34.2 at baseline to 19.3 at week 8) compared with a 13.2% decrease for placebo (34.2 at baseline to 29.7 at week 8, $p<0.001$). The rate of positive response (much improved or very much improved on the CGI-I) was 50% (N=15/30) for guanfacine compared with 9.4% (N=3/32) for placebo ($p=0.0001$; number needed to treat=2). Baseline and week 8 scores on all Aberrant Behavior Checklist subscales are presented in Table 2. The extended-release guanfacine group showed modest benefit on the Aberrant Behavior Checklist-stereotypy and inappropriate speech subscales (the latter remained significant after Bonferroni correction).

Cognitive Testing

Fifty-nine of 62 subjects had some cognitive testing results. Among those 59, complete data were available for 51 children,

with no difference in missing data across treatment groups. Performance scores at baseline and week 8 on the 17 subtests

TABLE 1. Baseline Characteristics of Children Randomly Assigned to Extended-Release Guanfacine or Placebo

Characteristic	Guanfacine (N=30)		Placebo (N=32)		p
	N	%	N	%	
Male	26	86.67	27	84.38	0.99
DSM-IV diagnosis					0.31
Autistic disorder	25	83.33	26	81.25	
Pervasive developmental disorder not otherwise specified	3	10.00	6	18.75	
Asperger's syndrome	2	6.67	0	0.00	
IQ^a					
<70	19	63.33	20	62.50	
≥70	11	36.67	10	31.25	
Clinical Global Impression-Severity					0.79 ^b
Moderately ill	12	40.00	12	37.50	
Markedly ill	17	56.67	17	53.13	
Severely ill	1	3.33	3	9.38	
Tanner stage					0.99
1 or 2	29	96.67	31	96.87	
3	1	3.33	1	3.13	
Race/ethnicity^c					0.34
White	17	56.67	23	68.75	
Black	7	23.3	4	12.50	
Asian	4	13.33	1	3.13	
Pacific Islander	1	3.33	1	3.13	
Mixed	1	3.33	3	9.38	
Maternal education					0.21
Less than high school	1	3.33	0	0.00	
High school graduate or GED	4	13.33	3	9.38	
Some college or post-high school or 2-year degree	4	16.67	12	34.37	
4-year college graduate	15	56.67	12	31.25	
Graduate or professional school	6	20.0	5	15.62	
School Placement					0.30
Regular class public or private school	16	53.3	21	65.62	
Special education program	14	46.7	10	31.25	
Home school	0	0.00	1	3.13	
	Mean	SD	Mean	SD	
Social Communication Questionnaire score	23.86	6.43	21.42	6.40	0.15
Vineland Adaptive Behavior Scales II score					
Socialization	66.80	14.35	67.12	14.88	0.93
Communication	72.92	20.07	73.50	13.66	0.40
Daily living	72.69	19.92	74.15	15.88	0.77
Aberrant Behavior Checklist					
Irritability	20.30	9.4	18.06	9.77	0.3623
Social withdrawal	13.60	9.43	12.06	9.29	0.5204
Stereotypy	8.53	5.69	9.31	5.56	0.5873
Hyperactivity	34.40	5.35	34.25	6.97	0.9250
Inappropriate speech	6.33	3.53	6.84	3.38	0.5628
ADHD Rating Scale					
Inattention	20.53	3.66	20.41	4.59	0.9048
Hyperactivity/impulsiveness	19.00	4.35	19.50	4.95	0.6750
Total	39.53	5.89	39.91	6.68	0.8169

^a Data are missing for two subjects in the placebo group.

^b The p value represents the proportion of subjects >moderate on Clinical Global Impression-Severity by group.

^c There were two Hispanic subjects in the active treatment arm and four in the placebo group.

TABLE 2. Scores on the Aberrant Behavior Checklist and ADHD Rating Scale at Baseline and Endpoint (Week 8)

Measure	Guanfacine (N=30)				Placebo (N=32)				p	Effect Size ^b
	Raw Mean		Least-Squares Mean ^a		Raw Mean		Least-Squares Mean ^a			
	Baseline	95% CI	Endpoint	95% CI	Baseline	95% CI	Endpoint	95% CI		
Aberrant Behavior Checklist Subscale										
Hyperactivity ^c	34.40	32.40–36.40	19.3	15.33–23.22	34.25	31.74–36.76	29.7	25.82–33.53	<0.0001	1.67
Irritability	20.30	16.79–23.81	13.5	10.01–17.06	18.06	14.54–21.58	16.1	12.68–19.54	0.20	0.27
Social withdrawal	13.60	10.08–17.12	9.8	7.26–12.27	12.06	8.71–15.41	8.6	6.10–11.02	0.41	0.13
Stereotypy	8.53	6.41–10.66	3.6	2.03–5.26	9.31	7.31–11.32	5.9	4.37–7.49	0.02	0.41
Inappropriate speech	6.33	5.02–7.65	4.2	3.24–5.26	6.84	5.63–8.06	5.99	4.50–6.97	0.004	0.50
ADHD Rating Scale										
Inattention	20.53	19.17–21.90	14.7	12.55–16.78	20.41	18.75–22.06	19.5	17.52–21.56	0.0001	1.17
Hyperactivity	19.00	17.38–20.62	10.6	8.50–12.75	19.50	17.71–21.29	18.7	16.6–20.69	<0.0001	1.72
Total	39.53	37.33–41.73	25.2	21.44–29.03	39.91	37.50–42.32	38.0	34.4–41.63	<0.0001	2.03

^a At week 8, the least-squares mean values on the hyperactivity subscale were within 1 standard deviation of the population mean; the least-squares mean values at endpoint are adjusted for baseline.

^b Effect sizes were calculated by taking the difference in the least-squares means at endpoint and dividing by the pooled standard deviation at baseline.

^c Raw baseline scores on the Aberrant Behavior Checklist-hyperactivity subscale were nearly 2 standard deviations above the population mean for developmentally disabled children 6 to 10 years of age.

analyzed are presented in Table 3. There were no group differences at baseline, and analysis of covariance models (adjusted for IQ ≥70 and <70) showed no group differences from baseline to endpoint on any subtests. The interactions between cognitive test scores at baseline and treatment were not significant. Examination on whether performance on any cognitive subtest predicted positive outcome in either treatment group was uninformative.

Medication Dose


The modal daily dose at week 8 was 3 mg/day (range: 1 mg/day–4 mg/day) for the extended-release guanfacine group and 3 mg/day (range: 2 mg/day–4 mg/day) for the placebo group.

Safety Results

The numbers and percentages of subjects with parent-reported mild, moderate, and severe adverse events are shown in Table 4. The adverse event labels in this table were derived from a list of preferred terms established before launching the study. The items on the Adverse Event Review and verbatim complaints were matched to the preferred terms. There was one serious adverse event in the guanfacine treatment group. Six days after the scheduled increase to 2 mg per day, the child (a 6 year-9-month-old boy) became verbally and physically aggressive toward his mother. The police were summoned, and the boy was taken to the emergency room. Upon evaluation, he was agitated and threatened hospital personnel, and his speech was pressured. The medication was discontinued, and he remained on the child psychiatric inpatient service for 3 days. Upon discharge, he was hyperactive and impulsive (similar to baseline). He was not agitated

or aggressive, and his speech was normal in tone and tempo. During the entire episode, there was no change in his sleep. The study medication was discontinued for this subject, but assessments were continued. One other subject in the guanfacine group also stopped treatment with the study drug because of adverse events and remained in the study for assessment. As shown in Figure 1, two subjects in the guanfacine group dropped out of the study completely because of multiple adverse events (drowsiness, fatigue, mid-sleep

FIGURE 2. Least-Squares Means on Aberrant Behavior Checklist-Hyperactivity Subscale Scores for Extended-Release Guanfacine and Placebo During the 8-Week Trial^a



^a Higher scores reflect greater hyperactivity. ABC= Aberrant Behavior Checklist.

TABLE 3. Scores on the Subtests of the Differential Ability Scales II and NEPSY II at Baseline and Endpoint (Week 8)

Cognitive Task	Guanfacine ^a				Placebo ^b				p ^c
	Baseline		Week 8		Baseline		Week 8		
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	
Differential Ability Scales Picture Recognition									
Raw score	5.59	3.45	5.65	4.02	6.67	4.77	6.86	4.38	0.79
Ability score	86.24	40.24	88.04	44.07	88.57	47.23	94.64	44.85	0.86
T-Score	34.45	14.51	34.77	16.18	37.57	21.51	39.29	20.87	0.94
Differential Ability Scales Recall of Digits									
Longest string correct	4.65	1.20	4.39	1.31	4.70	1.68	4.61	1.55	0.91
Raw score	12.81	6.23	12.04	7.03	14.07	7.55	13.90	7.61	0.81
Ability score	107.68	43.38	102.44	50.20	112.83	53.33	114.72	51.19	0.58
T-Score	33.21	14.22	32.36	16.80	36.27	17.63	35.62	17.83	0.41
NEPSY Hand Positions									
Dominant hand	1.83	0.38	1.88	0.33	1.97	0.18	1.93	0.26	0.31
Dominant hand raw score	6.17	3.27	6.65	3.42	5.40	3.59	6.69	3.72	0.32
Nondominant hand	1.21	0.41	1.12	0.33	1.07	0.25	1.07	0.26	0.62
Nondominant hand raw score	6.41	3.46	6.73	3.66	5.10	4.41	5.79	3.77	0.72
Total raw score	12.59	6.41	13.38	6.70	10.50	7.61	12.48	7.30	0.49
Total scaled score	5.00	2.55	5.36	2.41	4.46	3.16	5.64	3.72	0.47
NEPSY Manual Motor Sequences									
Highest item score	7.10	3.43	8.13	3.07	7.59	3.83	7.59	3.78	0.37
Total raw score	24.39	14.28	27.08	15.36	27.07	15.63	28.83	17.79	0.90
Percentile rank	2.00	1.04	2.15	1.05	2.32	1.12	2.50	1.23	0.61
Rate change	4.08	3.96	2.64	2.87	2.96	2.77	3.86	3.57	0.18

^a Sample sizes range from 25 to 29.

^b Sample sizes range from 27 to 30 due to missing data.

^c Data represent p values from the analysis of covariance models (adjusted for IQ ≥ 70 or < 70)

awakening, and emotional lability), and two dropped out because of lack of efficacy.

Nine subjects on active medication had a dose reduction because of suspected treatment-related adverse events (e.g., drowsiness, emotional/tearful presentation, irritability, and/or lowered blood pressure). Five placebo-treated subjects had dose adjustments in response to similar complaints. The term irritability reflects the combination of anger outbursts and low frustration tolerance, with disruptive behavior. By contrast, emotional/tearful captures what parents called “emotionally fragile” or “tearful and cranky.” Although less common, sleep disturbance (trouble falling asleep or mid-sleep awakening) also prompted dose reduction.

ECG data collected at screening and week 8 were reviewed by a board-certified pediatric cardiologist at each site. Mild, not clinically significant, ECG abnormalities were detected in 12 subjects at baseline and eight subjects at week 8 (active treatment, N=5; placebo, N=3). In guanfacine-treated subjects, sinus bradycardia was the most commonly reported finding. One subject had a borderline QTc prolongation of 461 ms at screening that was considered not clinically significant. At week 8, this subject had a QTc of 465, also considered not clinically significant. No subject had a QRS interval greater than 120 ms, and no other subject had a QTc greater than 450 ms. Systolic and diastolic blood pressure, as well as pulse, for 53 subjects with complete data across the 8-week trial are shown in Figure 3A, Figure 3B, and Figure 3C.

Sixteen subjects had a ≥ 10 -point drop in diastolic blood pressure in the guanfacine group compared with nine in the placebo group (p=0.04).

DISCUSSION

Extended-release guanfacine is approved by the U.S. Food and Drug Administration for the treatment of children with ADHD (28, 30). The results of this trial indicate that extended-release guanfacine is safe and effective for short-term treatment of hyperactivity, impulsiveness, and distractibility in children with ASD. The rate of positive response on the CGI-I is similar to what has been reported in previous trials of extended-release guanfacine in children with ADHD (28, 30). The results of the present study extend pilot study findings of immediate-release guanfacine in this population (16, 35). The primary outcome measure (Aberrant Behavior Checklist-hyperactivity subscale) includes items on hyperactivity, impulsiveness, inattention, and noncompliance that do not map directly on an ADHD diagnosis. On the DSM-IV-referenced ADHD Rating Scale (a key secondary measure), however, we also observed significant effects on hyperactivity, impulsiveness, and inattention.


The 43.6% decline in scores (effect size=1.67) on the parent-rated Aberrant Behavior Checklist-hyperactivity subscale from baseline to week 8 in this trial is greater than the 31%–38% reduction (effect sizes ranged from 0.29 to 0.54) across the three fixed-dose levels of methylphenidate in

TABLE 4. Adverse Events by Treatment Group Reported in >5% of Study Subjects

Adverse Event	Guanfacine		Placebo		p
	N	%	N	%	
Drowsiness	26	86.7	3	9.4	<0.001
Fatigue	19	63.3	3	9.4	<0.001
Decreased appetite	13	43.3	2	6.25	<0.001
Emotional/tearful	12	40	3	9.4	0.01
Dry mouth	12	40	1	3.1	<0.001
Irritability	11	36.7	3	9.4	0.01
Anxiety	9	30	1	3.13	0.01
Headache	9	30	6	18.75	0.30
Increased energy	9	30	6	18.75	0.30
Mid-sleep awakening	9	30	2	6.25	0.02
Stomachache	8	26.7	4	12.5	0.21
Constipation	7	23.3	2	6.25	0.08
Increased repetitive behavior	5	16.7	3	9.4	0.47
Aggression	5	16.7	2	6.25	0.25
Depressed mood	4	13.3	1	3.1	0.19
Cough/congestion	4	13.3	4	12.5	0.99
Self-injury	3	10	0	0	0.11
Nausea	3	10	2	6.25	0.67
Trouble falling asleep	3	10	2	6.25	0.67
Dizziness	3	10	2	6.25	0.67
Silly	3	10	5	15.6	0.71
Weakness	3	10	1	3.1	0.35
Diarrhea	3	10	0	0	0.11
Vomiting	3	6.7	3	9.4	0.99
Increased appetite	2	6.7	2	6.25	0.99
Excessive talking	2	6.7	9	28.1	0.04
Blurred vision	2	6.7	0	0	0.23
Skin rash/eczema	2	6.7	4	12.5	0.67
Nightmares	2	6.7	0	0	0.23
Enuresis	2	6.7	2	6.25	0.99
Motor tics	1	3.3	2	6.25	0.99
Skin picking	1	3.3	3	9.4	0.61
Fever	1	3.4	3	9.4	0.61

the crossover trial (12). However, on the predetermined algorithm used to define the optimal dose of methylphenidate, there was a 48% reduction (effect size=0.89) from baseline on the parent-rated Aberrant Behavior Checklist-hyperactivity subscale. The smaller effect size for the optimal dose in the methylphenidate study is due in part to the 22% decline in the placebo group in the prior study compared with a 13% decline in the guanfacine trial. Treatment for four of 30 guanfacine-treated subjects (13.3%) in the present study was discontinued because of adverse events (two remained in the study; two exited the study). By contrast, 18% (13 of 72) subjects discontinued the methylphenidate trial. On the CGI-I, the 50% positive response rate for guanfacine was nearly identical to the rate observed in the methylphenidate trial. Although it is difficult to compare the results of this 8-week parallel trial to the 4-week fixed-dose methylphenidate crossover trial, the magnitude of effect and tolerability appears slightly better for extended-release guanfacine for reducing ADHD symptoms in children with ASD. There are no identified predictors of positive response to either drug. Both drugs require careful monitoring to balance tolerability and benefits.

FIGURE 3. Mean Change From Baseline of Systolic Blood Pressure, Diastolic Blood Pressure, and Pulse Rate for Subjects With Complete Data by Treatment Condition



In the total score of the clinician-administered ADHD Rating Scale, we observed a 34% improvement from baseline to week 8 and a 50% positive response rate on the CGI-I. In an 8-week double-blind placebo-controlled trial of atomoxetine in 97 children with ASD and ADHD symptoms, Harfterkamp et al. (15) reported a 22% improvement on the ADHD Rating Scale and a 21% positive response rate on the CGI-I. These

contrasting results support the selection of extended-release guanfacine over atomoxetine in this clinical population.

The most common adverse events leading to dose reduction with extended-release guanfacine were drowsiness, fatigue, emotional fragility, tearfulness, and irritability. In a 5-week fixed-dose trial (placebo 2, 3, or 4 mg/day) of extended-release guanfacine, Biederman et al. (28) reported a similar pattern of adverse effects but at lower rates. Similarly, systolic and diastolic blood pressures and pulse declined during the dose escalation phase in the present study, which is consistent with findings in studies of extended-release guanfacine in children with ADHD (28). Blood pressure readings returned nearly to baseline measurements by week 8 in the present study. Heart rate remained about 10 points below baseline at week 8 in the guanfacine-treated group. There were no clinically significant changes from baseline on the ECG. These results suggest that monitoring blood pressure and pulse is warranted, especially early in treatment.

The α_2 agonists guanfacine and clonidine were developed as antihypertensives. The stimulation of presynaptic α_2 receptors reduces tonic firing of locus coeruleus neurons, resulting in slower heart rate and decreased blood pressure (36). A rich body of preclinical evidence indicates that norepinephrine neurons in the locus coeruleus also regulate arousal and play an essential role in interpretation of sensory stimuli and behavioral response (37). These multiple functions are managed by the balance of tonic and phasic firing of locus coeruleus neurons in concert with reciprocal cortical connections. Accumulated evidence over the past 25 years also demonstrates that guanfacine stimulates α_{2A} receptors in the prefrontal cortex, with potential benefits in working memory, attention, and impulse control (38). In the present study, we did not detect differences between guanfacine and placebo on tests of working memory or motor planning. It appears that guanfacine did not enhance or hinder cognitive functioning in this sample. Both mechanisms (reduced tonic firing of locus coeruleus neurons and stimulation of prefrontal α_{2A} receptors) may have contributed to the clinical results of this study.

Although symptoms of ADHD and ASD often co-occur and may reflect shared underlying genetic risk (39, 40), the ADHD syndrome in ASD may differ from ADHD in children without ASD. Children with ASD may be internally focused on topics of special interest, find little reward in matters outside of their circumscribed interest, and, consequently, pay little attention to other environmental stimuli. Hyperactivity and impulsiveness in children with ASD appear similar to the hyperactivity and impulsiveness in ADHD and are more amenable to measurement.

The significant improvement in ADHD symptoms in the guanfacine-treated group compared with placebo notwithstanding, the trial has several limitations. This study provides only acute efficacy and safety results. Furthermore, wide variability in school settings and enrollment during summer months precluded collection of teacher ratings. Finally, the sample size limits the ability to identify clinical characteristics that moderate treatment response.

AUTHOR AND ARTICLE INFORMATION

From the Department of Pediatrics, Emory University School of Medicine, Atlanta; the Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles; the Department of Psychiatry and Behavioral Sciences, Seattle Children's Hospital, Seattle, Wash.; the Department of Child and Adolescent Psychiatry, Lurie Center for Autism, Massachusetts General Hospital, Lexington, Mass.; the Marcus Autism Center, Atlanta; the Department of Biostatistics, Yale University, New Haven, Conn.; the Department of Emergency Medicine, Yale University, New Haven, Conn.; the Department of Psychiatry, Massachusetts General Hospital, Boston; and the David Geffen School of Medicine, University of California, Los Angeles.

Address correspondence to Dr. Scahill (Lawrence.scahill@emory.edu).

Supported by NIMH grants to Dr. Scahill (R01MH083707), Dr. McDougle (R01MH83739), Dr. McCracken (R01MH083747), and Dr. King (R01MH86927); by a Yale Clinical and Transitional Science Award (UL1 RR024139) from the NIH National Center for Research Resources; and by Atlanta Clinical and Translational Science Institute, Emory University, which is supported by the NIH National Center for Advancing Translational Sciences under award UL1TR000454.

Shire Pharmaceuticals provided active extended-release guanfacine and placebo.

The authors thank Yale Allison Gavaletz, B.A., and Caitlin Tillberg, B.A., for study coordination; Laura Simone for data management; Lily Katsovich, M.S., M.B.A., Gerald Golden, M.D., Christopher Young, M.D., and William Mahle, M.D., for serving on the data and safety monitoring board; and Nichole Evans for assistance with manuscript preparation.

Dr. Scahill has served as a consultant for Bracket, Coronado, MedAdvante, Neuren, Roche, and Shire, and he has served on the speaker's bureau for the Tourette Syndrome Association. Dr. McCracken has served as a consultant for Dart Neuroscience and Roche; he has received research support from Roche; he has received study drug and matching placebo from Shire; and he has served on the speaker's bureau for the Tourette Syndrome Association. Dr. King has received research support from Roche and Seaside Therapeutics. All other authors report no financial relationships with commercial interests.

Received Jan. 15, 2015; revision received April 9, 2015; accepted May 12, 2015.

REFERENCES

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders-Text Revised, 4th ed. Washington, DC, American Psychiatric Publishing, 2000
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC, American Psychiatric Publishing, 2013
3. Elsabbagh M, Divan G, Koh YJ, et al: Global prevalence of autism and other pervasive developmental disorders. *Autism Res* 2012; 5:160–179
4. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network: Risperidone in children with autism and serious behavioral problems. *N Engl J Med* 2002; 347:314–321
5. Hallett V, Lecavalier L, Sukhodolsky DG, et al: Exploring the manifestations of anxiety in children with Autism Spectrum Disorders. *J Autism Dev Disord* 2013; 43:2341–2352
6. Lecavalier L: Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification. *J Autism Dev Disord* 2006; 36:1101–1114
7. Gadow KD, DeVincent CJ, Pomeroy J: ADHD symptom subtypes in children with pervasive developmental disorder. *J Autism Dev Disord* 2006; 36:271–283
8. Simonoff E, Pickles A, Charman T, et al: Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. *J Am Acad Child Adolesc Psychiatry* 2008; 47:921–929

9. Kaat AJ, Lecavalier L, Aman MG: Validity of the Aberrant Behavior Checklist in children with autism spectrum disorder. *J Autism Dev Disord* 2014; 44:1103–1116
10. Rosenberg RE, Mandell DS, Farmer JE, et al: Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007–2008. *J Autism Dev Disord* 2010; 40:342–351
11. Ristow A, Westphal A, Scahill L: Treating hyperactivity in children with pervasive developmental disorders, in *Textbook of Autism Spectrum Disorders*. Edited by Hollander E, Kolevzon A, Coyle JT. Washington, DC, American Psychiatric Publishing, 2011, pp 479–789
12. Research Units on Pediatric Psychopharmacology Autism Network: Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. *Arch Gen Psychiatry* 2005; 62:1266–1274
13. Steele M, Jensen PS, Quinn DM: Remission versus response as the goal of therapy in ADHD: a new standard for the field? *Clin Ther* 2006; 28:1892–1908
14. The MTA Cooperative Group: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder: The MTA Cooperative Group: Multimodal Treatment Study of Children with ADHD. *Arch Gen Psychiatry* 1999; 56:1073–1086
15. Harfterkamp M, van de Loo-Neus G, Minderaa RB, et al: A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. *J Am Acad Child Adolesc Psychiatry* 2012; 51:733–741
16. Scahill L, Aman MG, McDougle CJ, et al: A prospective open trial of guanfacine in children with pervasive developmental disorders. *J Child Adolesc Psychopharmacol* 2006; 16:589–598
17. Guy W: *ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338*. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 218–222
18. Lord C, Risi S, Lambrecht L, et al: The Autism Diagnostic Observation Schedule–Generic: a standard measure of social and communication deficits associated with the spectrum of autism. *J Autism Dev Disord* 2000; 30:205–223
19. Corsello C, Hus V, Pickles A, et al: Between a ROC and a hard place: decision making and making decisions about using the SCQ. *J Child Psychol Psychiatry* 2007; 48:932–940
20. Roid GH: *Stanford-Binet Intelligence Scales*, 5th ed. Rolling Meadows, Ill, Riverside, 2003
21. Mullen EJ: *Mullen Scales of Early Learning*. Bloomington, Minn, Pearson Assessments, 1995
22. Gadow KD, Devincent CJ, Pomeroy J, et al: Comparison of DSM-IV symptoms in elementary school-age children with PDD versus clinic and community samples. *Autism* 2005; 9:392–415
23. Sparrow SS, Cicchetti DV, Balla DA: *Vineland-II Adaptive Behavior Scales*. Circle Pines, Minn, AGS Publishing, 2005
24. Brown EC, Aman MG, Havercamp SM: Factor analysis and norms for parent ratings on the Aberrant Behavior Checklist-Community for young people in special education. *Res Dev Disabil* 2002; 23:45–60
25. Aman MG, Singh NN, Stewart AW, et al: The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. *Am J Ment Defic* 1985; 89:485–491
26. DuPaul G, Power TJ, Anastopoulos AD, Reid R: *ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation*. New York, Guilford Press, 1998, pp 1–79
27. Michelson D, Allen AJ, Busner J, et al: Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. *Am J Psychiatry* 2002; 159:1896–1901
28. Biederman J, Melmed RD, Patel A, et al: A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. *Pediatrics* 2008; 121:e73–e84
29. Elliott C: *Differential Ability Scales-II (DAS-II)*. San Antonio, Tex, Pearson, 2007
30. Korkman M, Kirk U, Kemp S: *NEPSYII: Administration Manual*. San Antonio, Tex, Harcourt Assessment Inc, 2007
31. Board AW, Perry VP, Shepperson BE, et al: A postmarketing evaluation of guanfacine hydrochloride in mild to moderate hypertension. *Clin Ther* 1988; 10:761–775
32. Faraone SV, McBurnett K, Sallee FR, et al: Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents. *Clin Ther* 2013; 35:1778–1793
33. Gibbons RD, Hedeker D, Elkin I, et al: Some conceptual and statistical issues in analysis of longitudinal psychiatric data: application to the NIMH Treatment of Depression Collaborative Research Program dataset. *Arch Gen Psychiatry* 1993; 50:739–750
34. Molenberghs G, Thijs H, Jansen I, et al: Analyzing incomplete longitudinal clinical trial data. *Biostatistics* 2004; 5:445–464
35. Handen BL, Sahl R, Hardan AY: Guanfacine in children with autism and/or intellectual disabilities. *J Dev Behav Pediatr* 2008; 29:303–308
36. Hoffman BB: Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists, in *Goodman and Gilman's The Pharmacological Basis of Therapeutics*, 10th ed. Edited by Hardman JG, Limbird LE, Gilman AG. New York, McGraw-Hill, 2001, pp 215–268
37. Aston-Jones G, Cohen JD: Adaptive gain and the role of the locus coeruleus-norepinephrine system in optimal performance. *J Comp Neurol* 2005; 493:99–110
38. Arnsten AF, Pliszka SR: Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. *Pharmacol Biochem Behav* 2011; 99:211–216
39. Reiersen AM, Constantino JN, Volk HE, et al: Autistic traits in a population-based ADHD twin sample. *J Child Psychol Psychiatry* 2007; 48:464–472
40. Reiersen AM, Constantino JN, Todd RD: Co-occurrence of motor problems and autistic symptoms in attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 2008; 47:662–672